

## Cancer Center of Boston

[View the current Cancer Center of Boston Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/20391-Cancer+Center+of+Boston.html>)

### Contact Details:

61 Lincoln St. Suite 307

Framingham

Massachusetts

01702

United States of America

Tel: 617-739-6605

Fax: 617-739-4819

Email: [mbern@cancercenterofboston.com](mailto:mbern@cancercenterofboston.com)

The Cancer Center of Boston was established in September 1986 by Jacob J. Lokich, MD and Murray M. Bern, MD, formerly the chiefs of medical oncology and hematology, respectively, at the New England Deaconess Hospital. Their collaboration was based on the desire to develop a network of community based, freestanding facilities to diagnose and treat cancer and hematologic diseases with state-of-the-art therapies and access to clinical trials. Over the ensuing decade, the Boston facility has been expanded to include facilities or programs in Arlington (1987), Plymouth (1991) and Framingham (1994). In 2005, The Cancer Center relocated the Boston office to Chestnut Hill. Community based referrals are complemented by referrals from families and patients representing approximately 50% of all new patients. We see patients from regional, national and international locales, in part because of special areas of expertise such as infusion chemotherapy and participation on national and international clinical trial panels.

### Recent Publications by Cancer Center of Boston:



- [Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.](#)  
*OBJECTIVES: To determine if "same day" Pegfilgrastim (Pf) with CHOP...*10th August, 2006  
The Cancer Center of Boston, Chestnut Hill, MA, USA.- Am J Clin Oncol. 2006 Aug;29(4):361-3. ([DOI](#) [Direct Link](#))
- [Same-day pegfilgrastim and chemotherapy.](#)  
*Pegylated filgrastim is a new formulation of a neutrophil...*7th January, 2006  
The Cancer Center of Boston in Boston, Plymouth, and Framingham,- Cancer Invest. 2005;23(7):573-6. ([DOI](#) [Direct Link](#))
- [Coagulopathy, following medical therapy, for carcinoma of the prostate.](#)  
*Cancer of the prostate can be associated with coagulopathy characterized...*8th October, 2005  
The Cancer Center of Boston, Boston, MA 02120, USA.- Hematology. 2005 Feb;10(1):65-8. ([DOI](#)

[Direct Link](#))

- [Treatment of factor XI inhibitor using recombinant activated factor VIIa.](#)  
*A 30-year-old female with severe factor XI deficiency of 0-2% acquired...*26th May, 2005  
The Cancer Center of Boston, The New England Baptist Hospital, Harvard- Haemophilia. 2005 Jan;11(1):20-5. ([DOI Direct Link](#))
- [Tumor response and survival end points in clinical trials: a clinician's perspective.](#)  
*Survival has become the gold standard for determining the relative...*29th April, 2005  
The Cancer Center of Boston, Boston, Massachusetts 02120, USA.- Am J Clin Oncol. 2004 Oct;27(5):494-6.
- [Observations on possible effects of daily vitamin K replacement, especially upon warfarin therapy.](#)  
*Daily parenteral vitamin K supplement is now recommended by the U.S. Food...*9th April, 2005  
Cancer Center of Boston, New England Baptist Hospital, Harvard Medical- JPEN J Parenter Enteral Nutr. 2004 Nov-Dec;28(6):388-98.
- [Capecitabine: fixed daily dose and continuous \(noncyclic\) dosing schedule.](#)  
*BACKGROUND: Oral fluoropyrimidines are presumed to emulate a parenteral...*30th December, 2004  
The Cancer Center of Boston, Boston, Massachusetts, USA.- Cancer Invest. 2004;22(5):713-7.
- [Cutaneous hand and foot toxicity associated with cancer chemotherapy.](#)  
*The purpose was to determine the optimal multifractionated (MF) dosing...*20th February, 2004  
The Cancer Center of Boston in Boston, Massachusetts 02120, USA.- Am J Clin Oncol. 2003 Oct;26(5):435-6. ([DOI Direct Link](#))
- [Alternating doublets: establishing the optimal multifractionated dosing schedule to administer docetaxel, cisplatin, gemcitabine, and vinorelbine in combination.](#)  
*The purpose was to determine the optimal multifractionated (MF) dosing...*5th February, 2004  
Cancer Center of Boston, 125 Parker Hill Ave., Boston, Plymouth, MA- Cancer Invest. 2003;21(6):830-6.
- [Very low dose warfarin as prophylaxis against ultrasound detected deep vein thrombosis following primary hip replacement.](#)  
*One mg daily warfarin was compared to variable dose warfarin (PT 1.3-1.5...*26th November, 2002  
The Cancer Center of Boston, Boston, Massachusetts, USA.- Am J Hematol. 2002 Oct;71(2):69-74. ([DOI Direct Link](#))

## Press Releases on Cancer Center of Boston:

### [NVHR: New Data Finding](#)

[Fewer than 1 in 5](#)

[Hepatitis C Patients](#)

[Receiving Antiviral](#)

[Therapy is](#)

['s;Wake-Up](#)

[Call's; for](#)

[Washington](#)

24th November,  
2009

National Viral  
Hepatitis Roundtable

WASHINGTON, Nov. 24  
/PRNewswire-USNewswire/ -- New  
peer-reviewed data finding that fewer  
than one-fifth of the nearly 4 million  
Americans infected with chronic  
hepatitis C virus have received anti

### [YM BIOSCIENCES](#)

[REPORTS FIRST](#)

[PATIENT IN PHASE I/II](#)

[TRIAL OF JAK1/JAK2](#)

[INHIBITOR, CYT387](#)

[ENROLLED BY](#)

[CYTOPIA](#)

23rd November,  
2009

YM BioSciences Inc.

MISSISSAUGA, ON, Nov. 23  
/PRNewswire-FirstCall/ - YM  
BioSciences Inc. (NYSE Amex: YMI;  
TSX: YM), a life sciences product  
development company that identifies  
and advances a diverse portfolio of

[NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference](#)

23rd November, 2009

NuVasive, Inc.

SAN DIEGO, Nov. 23 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine,

[InSite One Announces the First Health Information Exchange Within a Unified Enterprise Archive](#)

23rd November, 2009

InSite One, Inc.

WALLINGFORD, Conn., Nov. 23 /PRNewswire/ -- InSite One, Inc, the industry's leading provider of medical data archiving and disaster recovery managed services, announces the creation of the first

[Bally Total Fitness Offers Expert Tips on Fighting Fat for the Holidays](#)

23rd November, 2009

Bally Total Fitness

CHICAGO, Nov. 23 /PRNewswire/ -- Eat, drink and be merry sounds like a festive way to savor the holiday season, but it's also a guaranteed way to pack on the pounds before the New Year. Instead

## BioNews Results for Cancer Center of Boston



- [Jury Still Out on Whether Advanced Technology Can Improve the Outcomes of Patients With Anal Canal Cancer](#)  
*Cancernetwork.com: Nov 15 2009 1:11AM Matching: cancer center boston*
- [Dana-Farber Cancer Institute Selects Plateau Systems' Integrated Talent Management Suite](#)  
*Media Newswire: Nov 13 2009 6:58AM Matching: cancer center boston*
- [OXIGENE to Present at American Society of Hematology and AACR/NCI/EORTC Meetings](#)  
*Pharmacy Choice: Nov 13 2009 6:25AM Matching: cancer center boston*
- [Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI-EORTC Int](#)  
*Pharmacy Choice: Nov 13 2009 6:26AM Matching: cancer center boston*
- [Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI-EORTC Int](#)  
*Genetic Engineering News: Nov 13 2009 12:13AM Matching: cancer center boston*
- [Aspirin shows promise for colon cancer patients](#)  
*WTVM: Nov 12 2009 9:21AM Matching: cancer center boston*
- [Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI-EORTC Int](#)  
*Yahoo! Canada: Nov 12 2009 9:04PM Matching: cancer center boston*
- [Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 2009 AACR-NCI](#)  
*Interest!ALERT: Nov 12 2009 9:32PM Matching: cancer center boston*
- [Nodal Staging Score: A Tool to Assess Adequate Staging of Node-Negative Colon Cancer \[Gastrointestinal Cancer\]](#)  
*Journal of Clinical Oncology: Nov 11 2009 8:40PM Matching: cancer center boston*

- [Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer,](#)  
*Journal of Clinical Oncology: Nov 11 2009 8:39PM Matching: cancer center boston*
- [Poniard Pharmaceuticals to Present Updated Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer](#)  
*Pharma Live: Nov 11 2009 4:47AM Matching: cancer center boston*
- [Conjugated Equine Estrogen Influence on Mammographic Density in Postmenopausal Women in a Substudy of the Wome](#)  
*Journal of Clinical Oncology: Nov 11 2009 8:38PM Matching: cancer center boston*
- [Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Lef](#)  
*Journal of Clinical Oncology: Nov 11 2009 8:38PM Matching: cancer center boston*
- [Right Brains Wanted: Sanofi-Aventis Wants to Tap the Creative Genius of Boston-Area Biotechs](#)  
*Xconomy: Nov 11 2009 5:39AM Matching: cancer center boston*
- [Sunesis to Present Nonclinical Voreloxin Combination Data at AACR-EORTC-NCI Conference](#)  
*Pharma Live: Nov 11 2009 4:48AM Matching: cancer center boston*

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.  
UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,  
Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

